ARID1A and neoplasm: In addition, Hu et al. (2018) revealed that the blockage of Ang2 could reverse the change of tumor behaviors induced by ARID1A alterations or expression loss which uncovers the potentiality of anti-angiogenic therapy in overcoming the resistance to EGFR-TKIs, such as the treatment of EGFR-TKIs combined with bevacizumab.